Q3 2022 EPS Estimates for AbbVie Inc. Lowered by SVB Leerink (NYSE:ABBV)
Q3 2022 EPS Estimates for AbbVie Inc. Lowered by SVB Leerink (NYSE:ABBV)
AbbVie Inc. (NYSE:ABBV – Get Rating) – Investment analysts at SVB Leerink lowered their Q3 2022 EPS estimates for shares of AbbVie in a research note issued on Friday, September 30th. SVB Leerink analyst G. Porges now forecasts that the company will earn $3.58 per share for the quarter, down from their prior forecast of $3.59. The consensus estimate for AbbVie's current full-year earnings is $14.06 per share. SVB Leerink also issued estimates for AbbVie's Q4 2022 earnings at $3.81 EPS and FY2022 earnings at $14.06 EPS.
艾伯維公司。(紐約證券交易所代碼：ABBV-GET Rating)-SVB Leerink的投資分析師在9月30日星期五發布的一份研究報告中下調了對艾伯維股票2022年第三季度每股收益的預期。SVB Leerink分析師G.Porges現在預測，該公司本季度每股收益為3.58美元，低於此前預測的3.59美元。對艾伯維目前全年收益的普遍預期為每股14.06美元。SVB Leerink還發布了對AbbVie 2022財年第四季度每股收益3.81美元和2022財年每股收益14.06美元的預期。
ABBV has been the subject of a number of other research reports. Argus dropped their price objective on shares of AbbVie from $165.00 to $155.00 and set a "buy" rating for the company in a research note on Wednesday, August 24th. Barclays dropped their price objective on shares of AbbVie to $160.00 in a research note on Tuesday, August 9th. Atlantic Securities dropped their price objective on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a research note on Monday, August 1st. UBS Group dropped their price objective on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a research note on Monday, August 1st. Finally, Piper Sandler dropped their target price on shares of AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $159.35.
ABBV已經成為許多其他研究報告的主題。8月24日，阿格斯在一份研究報告中將艾伯維股票的目標價從165.00美元下調至155.00美元，併為該公司設定了“買入”評級。巴克萊在8月9日週二的一份研究報告中將艾伯維股票的目標價下調至160.00美元。大西洋證券將艾伯維股票的目標價從178.00美元下調至162.00美元，並在8月1日星期一的一份研究報告中對該公司設定了“中性”評級。8月1日，瑞銀集團在一份研究報告中將艾伯維股票的目標價從154.00美元下調至146.00美元，並將該公司的評級定為“中性”。最後，派珀·桑德勒在7月29日星期五的一份研究報告中將艾伯維股票的目標價從160.00美元下調至155.00美元。一名投資分析師對該股的評級為賣出，六名分析師給予持有評級，九名分析師給予該股買入評級，一名分析師給予該股強烈買入評級。根據MarketBeat，該股目前的平均評級為“中等買入”，平均目標價為159.35美元.
AbbVie Trading Down 6.0 %
AbbVie股價下跌6.0%
AbbVie (NYSE:ABBV – Get Rating) last issued its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share for the quarter, beating analysts' consensus estimates of $3.42 by $0.09. AbbVie had a net margin of 22.03% and a return on equity of 158.41%. The firm had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $14.64 billion. During the same period in the prior year, the firm earned $3.11 EPS. The business's revenue was up 4.5% on a year-over-year basis.
艾伯維(紐約證券交易所代碼：ABBV-GET Rating)上一次發佈季度收益報告是在7月29日星期五。該公司公佈本季度每股收益為3.51美元，比分析師普遍預期的3.42美元高出0.09美元。艾伯維的淨利潤率為22.03%，股本回報率為158.41%。該公司本季度營收為145.8億美元，而市場普遍預期為146.4億美元。去年同期，該公司每股收益為3.11美元。該業務的收入同比增長了4.5%。
AbbVie Dividend Announcement
AbbVie股息公告
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Shareholders of record on Friday, October 14th will be given a $1.41 dividend. This represents a $5.64 annualized dividend and a yield of 4.20%. The ex-dividend date is Thursday, October 13th. AbbVie's payout ratio is presently 79.89%.
該業務最近還披露了季度股息，將於11月15日(星期二)支付。10月14日(星期五)登記在冊的股東將獲得1.41美元的股息。這意味着5.64美元的年化股息和4.20%的收益率。除息日期為10月13日星期四。艾伯維目前的派息率為79.89%。
Institutional Inflows and Outflows
機構資金流入和流出
Several hedge funds have recently modified their holdings of the business. Capital International Investors boosted its stake in AbbVie by 162.6% during the 1st quarter. Capital International Investors now owns 30,497,767 shares of the company's stock worth $4,943,993,000 after acquiring an additional 18,882,699 shares during the last quarter. Norges Bank acquired a new position in AbbVie during the fourth quarter worth $2,433,269,000. Vanguard Group Inc. increased its holdings in AbbVie by 2.9% during the first quarter. Vanguard Group Inc. now owns 150,518,780 shares of the company's stock worth $24,400,600,000 after buying an additional 4,206,711 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in AbbVie by 426.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 4,652,122 shares of the company's stock worth $754,155,000 after buying an additional 3,768,579 shares during the last quarter. Finally, GQG Partners LLC boosted its position in AbbVie by 1,706.1% during the second quarter. GQG Partners LLC now owns 3,051,620 shares of the company's stock worth $467,658,000 after purchasing an additional 2,882,655 shares during the period. Institutional investors own 68.25% of the company's stock.
幾家對衝基金最近調整了對該業務的持股。第一季度，Capital International Investors將其在AbbVie的持股比例提高了162.6%。Capital International Investors現在擁有30,497,767股該公司股票，價值4,943,993,000美元，在上個季度增持了18,882,699股。挪威銀行在第四季度收購了AbbVie的一個新頭寸，價值2433269,000美元。先鋒集團在第一季度增持了2.9%的艾伯維股份。先鋒集團現在持有150,518,780股該公司股票，價值24,400,600,000美元，在上個季度又購買了4,206,711股。ArrowStreet Capital Limited Partnership在第一季度增加了對AbbVie的持股426.5%。ArrowStreet Capital Limited Partnership現在擁有4652,122股該公司股票，價值754,155,000美元，上個季度又購買了3,768,579股。最後，GQG Partners LLC在第二季度將其在AbbVie的頭寸增加了1706.1%。在此期間，GQG Partners LLC額外購買了2,882,655股，目前擁有3,051,620股該公司股票，價值467,658,000美元。機構投資者持有該公司68.25%的股份。
AbbVie Company Profile
艾伯維公司簡介
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA，用於注射治療自身免疫和腸道Behçet‘s疾病；SKYRIZI用於治療成人中到重度斑塊型牛皮癬；RINVOQ，用於治療成人患者的中到重度活動性類風濕性關節炎；IMBRUVICA，用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤；以及VENCLEXTA，用於治療成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- 阿徹·丹尼爾斯·米德蘭：49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎？
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。